Genetic Immunity said that it has implemented ‘Quality-by-Design’ in biologic product development to manufacture a nanomedicine resulting in a new formulation of pDNA surrounded by a chemical polymer
Inhibitex has posted a net loss of $4.8m for the first quarter 2010, or $ 0.08 per diluted share, compared to $4.20m, or $ 0.10 per diluted share,
As per the agreement, Abbott is expected to gain rights to at least 24 Zydus products in 15 key emerging markets where Abbott has a growing presence. The
For the first quarter of 2010, Ranbaxy Laboratories has posted a EBITDA of $298m, compared to a loss of $201m for the prior year period. Profit after tax
The settlement is expected to resolve more than 700 lawsuits related to Avandia. Currently, there are around 4,000 cases that are yet to follow. The officials of GSK
Evotec has posted a net loss of EUR1.2m for the first quarter 2010, or EUR 0.01 per diluted share, compared to EUR21.8m, or EUR 0.21 per diluted share,
Sanofi-aventis said that the rationale of the trial was based on post-hoc findings from the Athena trial, in which a trend towards reduction of CV hospitalisation and death
According to the FDA, Cefepime should be used only to treat or prevent bacterial infections in hospitals and healthcare centers. And especially, the infections that are proven or
Under the terms of the agreement, GSK gains certain rights to Response Genetics’ PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples.
On May 7, 2010, IntelGenx executed a project transfer agreement with Cary Pharmaceuticals, its former development partner, whereby Cary assigned its 50% ownership stake in CPI-300 to IntelGenx.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.